Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug-gene interactions

• Main Authors: Elena Peruzzi (Author), Bianca Posocco (Author), Lorenzo Gerratana (Author), Margherita Nuti (Author), Marco Orleni (Author), Sara Gagno (Author), Elena De Mattia (Author), Fabio Puglisi (Author), Erika Cecchin (Author), Giuseppe Toffoli (Author), Rossana Roncato (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Palbociclib, an oral inhibitor of cyclin-dependent kinase 4 and 6, is approved for the treatment of metastatic breast cancer. This study investigated the influence of diverse clinical and biological factors-age, renal function, genetic variations, and concomitant medications (pharmacokinetic covaria...